País: Portugal
Idioma: inglés
Fuente: HMA (Heads of Medicines Agencies)
amoxicillin trihydrate 50 mg, clavulanic acid 12.5 mg
Le Vet B.V
QJ01CR01
Tablet
ampicillin and enzyme inhibitor
Cats, Dogs
2011-03-30
Page 1 of 17 SUMMARY OF PRODUCT CHARACTERISTICS 2 1. NAME OF THE VETERINARY MEDICINAL PRODUCT CLAVUBACTIN® 50/12.5 MG tablets for cats and dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION ACTIVE SUBSTANCES: _quantity _ Amoxicillin (as amoxicillin trihydrate) 50 mg Clavulanic acid (as potassium clavulanate) 12.5 mg EXCIPIENT(S): Saccharin sodium 0.70 mg For a full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Tablet Yellowish-white to light yellow oblong tablet with breakmark on both sides. 4. CLINICAL PARTICULARS 4.1 TARGET SPECIES Dogs and cats 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES Treatment of infections in cats and dogs caused by bacteria sensitive to amoxicillin in combination with clavulanic acid, particularly: - Skin infections (including superficial and deep pyodermas) associated with Staphylococci (including beta-lactamase producing strains) and Streptococci. - Urinary tract infections associated with Staphylococci (including beta-lactamase producing strains), Streptococci, _Escherichia coli _(including beta-lactamase producing strains), _Fusobacterium _ _necrophorum _and _Proteus spp_. - Respiratory tract infections associated with Staphylococci (including beta-lactamase producing strains), Streptococci and Pasteurellae. - Enteritis associated with _Escherichia coli _(including beta-lactamase producing strains) and Proteus spp. - Infections of the oral cavity (mucous membrane) associated with Clostridia, Corynebacteria, Staphylococci (including beta-lactamase producing strains), Streptococci, _Bacteroides spp _ (including beta-lactamase producing strains), _Fusobacterium necrophorum _and Pasteurellae. Leer el documento completo